These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 23646111)
21. Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients. Casado JL; Marín A; Moreno A; Iglesias V; Perez-Elías MJ; Moreno S; Corral I J Neurovirol; 2014 Feb; 20(1):54-61. PubMed ID: 24420449 [TBL] [Abstract][Full Text] [Related]
22. Neurocognitive functioning of HIV positive children attending the comprehensive care clinic at Kenyatta national hospital: exploring neurocognitive deficits and psychosocial risk factors. Musindo O; Bangirana P; Kigamwa P; Okoth R; Kumar M AIDS Care; 2018 May; 30(5):618-622. PubMed ID: 29353495 [TBL] [Abstract][Full Text] [Related]
23. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Marra CM; Lockhart D; Zunt JR; Perrin M; Coombs RW; Collier AC Neurology; 2003 Apr; 60(8):1388-90. PubMed ID: 12707454 [TBL] [Abstract][Full Text] [Related]
25. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255 [TBL] [Abstract][Full Text] [Related]
26. Evidence for neuropsychological health disparities in Black Americans with HIV disease. Thompson JL; Beltran-Najera I; Johnson B; Morales Y; Woods SP Clin Neuropsychol; 2022 Feb; 36(2):388-413. PubMed ID: 35166174 [TBL] [Abstract][Full Text] [Related]
27. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803 [TBL] [Abstract][Full Text] [Related]
28. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
29. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. Winston A; Puls R; Kerr SJ; Duncombe C; Li PC; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA; HIV Med; 2012 Apr; 13(4):245-51. PubMed ID: 22151608 [TBL] [Abstract][Full Text] [Related]
36. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy. Garvey LJ; Yerrakalva D; Winston A AIDS Res Hum Retroviruses; 2009 Aug; 25(8):765-9. PubMed ID: 19678764 [TBL] [Abstract][Full Text] [Related]
37. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial. Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L; J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603 [TBL] [Abstract][Full Text] [Related]
38. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721 [TBL] [Abstract][Full Text] [Related]
39. Cognitive reserve and neuropsychological functioning in older HIV-infected people. Milanini B; Ciccarelli N; Fabbiani M; Limiti S; Grima P; Rossetti B; Visconti E; Tamburrini E; Cauda R; Di Giambenedetto S J Neurovirol; 2016 Oct; 22(5):575-583. PubMed ID: 26965299 [TBL] [Abstract][Full Text] [Related]
40. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]